This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lipshultz, S. E. Articles by Colan, S. D. Search for Related Content PubMed PubMed Citation Articles by Lipshultz, S. E. Articles by Colan, S. D. Social Bookmarking                            What's this?

Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia

From the Department of Pediatrics, Miller School of Medicine at the Univerity of Miami, Holtz Children's Hospital, and Sylvester Comprehensive Cancer Center, Miami, FL; Department of Pediatric Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, Division of Hematology/Oncology and Department of Cardiology, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA; Department of Biometry and Epidemiology, Medical University of S Carolina, Charleston, SC

Address reprint requests to Steven E. Lipshultz, MD, Department of Pediatrics (D820), Miller School of Medicine at the University of Miami, PO Box 016820, Miami, FL 33101. Express mail address: Department of Pediatrics, Miller School of Medicine at the University of Miami, Medical Campus-MCCD-D820, 1601 NW 12th Ave, 9th Floor, Miami, FL 33136; e-mail: slipshultz{at}med.miami.edu

PURPOSE: Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare.

METHODS: Serial echocardiograms (N = 499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years). Results were expressed as z scores to indicate the number of standard deviations (SDs) above (+) or below (–) the normal predicted value. Median individual and cumulative doxorubicin doses were 30 mg/m² per dose and 352 mg/m², respectively.

RESULTS: Left ventricular fractional shortening was significantly reduced after doxorubicin therapy, and the reduction was related to cumulative dose. z scores for fractional shortening transiently improved before falling to –2.76 more than 12 years after diagnosis. Reduced fractional shortening was related to impaired contractility and increasing afterload, consequences of a progressive reduction of ventricular mass, and wall thickness relative to body-surface area. Left ventricular contractility fell significantly over time and was depressed at last follow-up in patients receiving more than 300 mg/m² of doxorubicin. Systolic and diastolic blood pressures were below normal more than 9 years after diagnosis. Even patients receiving lower cumulative doxorubicin doses experienced reduced mass and dimension. Fractional shortening and dimension at the end of therapy predicted these parameters 11.8 years later.

CONCLUSION: Cardiac abnormalities were persistent and progressive after doxorubicin therapy. Inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced cardiac output and restrictive cardiomyopathy. The deficits were worst after highest cumulative doses of doxorubicin, but appeared even after low doses.

Supported by grants from the National Institutes of Health (CA 68484, CA 55576, CA 06516, CA 79060, HL 59837, HR 96041, HL 53392, HL 72705, and HL 69800).

This study was presented in part as an abstract at the American Society of Clinical and Oncology and the American Heart Association annual sessions.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. B. Haddy, R. B. Mosher, and G. H. Reaman Late Effects in Long-Term Survivors After Treatment for Childhood Acute Leukemia Clinical Pediatrics, July 1, 2009; 48(6): 601 - 608. [Abstract] [PDF]

				C. P. Miller, S. Rudra, M. J. Keating, W. G. Wierda, M. Palladino, and J. Chandra Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells Blood, April 30, 2009; 113(18): 4289 - 4299. [Abstract] [Full Text] [PDF]

				D. S. Hydock, C.-Y. Lien, and R. Hayward Anandamide Preserves Cardiac Function and Geometry in an Acute Doxorubicin Cardiotoxicity Rat Model Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 59 - 67. [Abstract] [PDF]

				S. H. Armenian, C.-L. Sun, L. Francisco, J. Steinberger, S. Kurian, F. L. Wong, J. Sharp, R. Sposto, S. J. Forman, and S. Bhatia Late Congestive Heart Failure After Hematopoietic Cell Transplantation J. Clin. Oncol., December 1, 2008; 26(34): 5537 - 5543. [Abstract] [Full Text] [PDF]

				D. Pulte, A. Gondos, and H. Brenner Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004 J Natl Cancer Inst, September 17, 2008; 100(18): 1301 - 1309. [Abstract] [Full Text] [PDF]

				L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer Anthracycline Cardiotoxicity: From Bench to Bedside J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784. [Abstract] [Full Text] [PDF]

				S. H. Armenian and S. Bhatia Cardiovascular disease after hematopoietic cell transplantation - lessons learned Haematologica, August 1, 2008; 93(8): 1132 - 1136. [Full Text] [PDF]

				A. Moricke, A. Reiter, M. Zimmermann, H. Gadner, M. Stanulla, M. Dordelmann, L. Loning, R. Beier, W.-D. Ludwig, R. Ratei, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood, May 1, 2008; 111(9): 4477 - 4489. [Abstract] [Full Text] [PDF]

				S. E Lipshultz, J. A Alvarez, and R. E Scully Anthracycline associated cardiotoxicity in survivors of childhood cancer Heart, April 1, 2008; 94(4): 525 - 533. [Full Text] [PDF]

				E. C. van Dalen and L. C. M. Kremer Effect of Dosing Schedules on Anthracycline-induced Cardiotoxicity in Children with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 442 - 447. [Abstract] [Full Text] [PDF]

				E. V. Barry, S. E. Lipshultz, and S. E. Sallan Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention ASCO Educational Book, January 1, 2008; 2008(1): 448 - 453. [Abstract] [Full Text] [PDF]

				R. E. Scully, T. L. Miller, and S. E. Lipshultz Detecting Anthracycline-induced Cardiotoxicity in Survivors of Childhood Cancer ASCO Educational Book, January 1, 2008; 2008(1): 454 - 458. [Abstract] [Full Text] [PDF]

				L. W. Jones, M. Haykowsky, E. N. Pituskin, N. G. Jendzjowsky, C. R. Tomczak, R. G. Haennel, and J. R. Mackey Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer Oncologist, October 1, 2007; 12(10): 1156 - 1164. [Abstract] [Full Text] [PDF]

				J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008. [Abstract] [Full Text] [PDF]

				M. M. Hudson, S. N. Rai, C. Nunez, T. E. Merchant, N. M. Marina, N. Zalamea, C. Cox, S. Phipps, R. Pompeu, and D. Rosenthal Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors J. Clin. Oncol., August 20, 2007; 25(24): 3635 - 3643. [Abstract] [Full Text] [PDF]

				J. D. Boice Jr An Affair of the Heart J Natl Cancer Inst, February 7, 2007; 99(3): 186 - 187. [Full Text] [PDF]

				A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood, February 1, 2007; 109(3): 896 - 904. [Abstract] [Full Text] [PDF]

				L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741. [Abstract] [Full Text] [PDF]

				K. C. Oeffinger, A. C. Mertens, C. A. Sklar, T. Kawashima, M. M. Hudson, A. T. Meadows, D. L. Friedman, N. Marina, W. Hobbie, N. S. Kadan-Lottick, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N. Engl. J. Med., October 12, 2006; 355(15): 1572 - 1582. [Abstract] [Full Text] [PDF]

				C. Brouwer, J. Gietema, M. van den Berg, M. Bink-Boelkens, N. Elzenga, J Haaksma, W. Kamps, J. Vonk, E. de Vries, and A Postma Long-term cardiac follow-up in survivors of a malignant bone tumour Ann. Onc., October 1, 2006; 17(10): 1586 - 1591. [Abstract] [Full Text] [PDF]

				K. Li, R. Y. T. Sung, W. Z. Huang, M. Yang, N. H. Pong, S. M. Lee, W. Y. Chan, H. Zhao, M. Y. To, T. F. Fok, et al. Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin Circulation, May 9, 2006; 113(18): 2211 - 2220. [Abstract] [Full Text] [PDF]

				C.-H. Pui and W. E. Evans Treatment of Acute Lymphoblastic Leukemia N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178. [Full Text] [PDF]